37 results about "Valvular regurgitation" patented technology

A system for treating mitral valve regurgitation includes a tensioning device having a plurality of helical anchors and a tensioning filament. One embodiment of the invention includes a method for attaching a tensioning device to the annulus of a mitral valve in a trans-leaflet configuration, and applying a tension force to the tension filament in order to exert force vectors on the annulus, thereby reshaping the mitral valve annulus so that the coaption of the anterior and posterior leaflets of the mitral is improved during ventricular contraction.

The invention relates to a device for use in the transcatheter treatment of mitral valve regurgitation, specifically a coaptation assistance element for implantation across the valve; a system including the coaptation assistance element and anchors for implantation; a system including the coaptation assistance element and delivery catheter; and a method for transcatheter implantation of a coaptation element across a heart valve.

A system for treating valvular regurgitation in a heart valve includes a flexible canopy and an elongated tether including an elastic portion and an inelastic portion. When the system is in a deployed configuration, a proximal end of the flexible canopy is coupled to an annulus of the heart valve and a distal end of the elongated tether is coupled to a ventricle. The flexible canopy is configured to overlay a first native leaflet of the heart valve, and tension on the elongated tether is applied and/or adjusted to prevent the first leaflet from prolapsing, to maximize coaptation of the flexible canopy with a second native leaflet of the heart valve, and to minimize regurgitation of the heart valve.

The invention relates to a device for use in the transcatheter treatment of mitral valve regurgitation, specifically a coaptation assistance element for implantation across the valve; a system including the coaptation assistance element and anchors for implantation; a system including the coaptation assistance element and delivery catheter; and a method for transcatheter implantation of a coaptation element across a heart valve.

The invention relates to a device for use in the transcatheter treatment of mitral valve regurgitation, specifically a coaptation assistance element for implantation across the valve; a system including the coaptation assistance element and anchors for implantation; a system including the coaptation assistance element and delivery catheter; and a method for transcatheter implantation of a coaptation element across a heart valve.

In vitro performance testing system and testing methods for transcatheter mitral valve stents, involving implantable prostheses, in particular testing devices and testing methods for performance testing of heart valves, including valves with built-in mitral valve stents Test parts, liquid circulation device and monitoring device; the first test part is a heart sample with a circulation inlet at the apex of the left ventricle, and the second test part is a section of artificial blood vessel or blood vessel sample for suturing the tested mitral valve stent; liquid circulation device It is connected with the first test part to form a first test circulation path of steady flow circulation or a second test circulation path that simulates human ventricular pulsation; the liquid circulation device is connected to the second test part to form a third test circulation path connected by circulation side branches, It can realize the in vitro test of the hydrodynamic performance of the mitral valve stent, stent fixation state, valve regurgitation, paravalvular leakage, and the impact on the surrounding important tissue structure, and complete the durability test of the mitral valve stent.

Techniques are provided for use with a pulmonary artery pressure (PAP) monitor having an implantable PAP sensor. In one example, a PAP signal is sensed that is representative of beat-by-beat variations in PAP occurring during individual cardiac cycles of the patient. The PAP monitor detects peaks within the PAP signal corresponding to valvular regurgitation within the heart, then detects mitral regurgitation (MR) based on the peaks. In other examples, the PAP monitor optimizes pacing parameters based on the PAP signal and corresponding electrical cardiac signals. Examples are provided where the PAP monitor is an external system and other examples are provided where the PAP monitor is a component of an implantable cardiac rhythm management device.

The present invention is provides methods and formulations for preventing or ameliorating progression to chronic heart failure subsequent to cardiac stress, including as a consequence of myocardial infarction (MI), coronary artery disease, hypertension, cardiomyopathy, myocarditis, valvular regurgitation, severe lung disease, and/or severe anemia of chronic disease, by administration of one or more rate-limiting precursors to the synthesis of ATP. In one embodiment the ATP precursor is a pentose selected from one or more of ribose, D-ribose, ribulose, xylitol, xylulose, and a 5-carbon precursor of ribose.

The invention concerns the treatment of cardiac hypertrophy by interferon-gamma (IFN-γ). Cardiac hypertrophy may result from a variety of diverse pathologic conditions, including myocardial infarction, hypertension, hypertrophic cardiomyopathy, and valvular regurgitation. The treatment extends to all stages of the progression of cardiac hypertrophy, with or without structural damage of the heart muscle, regardless of the underlying cardiac disorder.

The present disclosure relates to a device for valve regurgitation surgery and pacemaker lead fixation, and more particularly, to a device for valve regurgitation surgery and pacemaker lead fixation that allows mitral regurgitation surgery, tricuspid regurgitation surgery, and fixation of a pacemaker lead to an interventricular septum to be performed using a single device. The device for valve regurgitation surgery and pacemaker lead fixation according to the present disclosure includes a cerclage wire, a coronary sinus tube which has a lumen formed to insert the cerclage wire thereinto and which is inserted into a coronary sinus, a tricuspid valve tube which has a lumen formed to insert the cerclage wire thereinto and which crosses a tricuspid valve and protects tissues of the tricuspid valve and the interventricular septum, a lead insertion tube which is coupled to the tricuspid valve tube and has an end facing the interventricular septum, and a pacemaker lead which is inserted into the lead insertion tube and has an end inserted into the bundle of His.